<DOC>
	<DOC>NCT01032486</DOC>
	<brief_summary>The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.</brief_summary>
	<brief_title>Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>idiopathic Parkinson's disease. eligible to Azilect® treatment as per Canadian product monograph exclusion (e.g. drugdrug interactions, contraindications, warnings and precautions) based on the Canadian product monograph. investigational drug within 30 days prior to study use of Azilect® or selegiline within 60 days prior to study significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rasagiline</keyword>
	<keyword>Sleep</keyword>
	<keyword>Sleepiness</keyword>
	<keyword>Parkinson's Disease Sleep Scale</keyword>
	<keyword>Epworth Sleepiness Scale</keyword>
</DOC>